BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 6644351)

  • 1. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
    Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
    J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
    Edwards BS; Hawkins MJ; Borden EC
    J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS; Hawkins MJ; Borden EC
    Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS; Brandt CP; Tso CY; Laszlo J
    J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J.
    Platsoucas CD; Fox FE; Oleszak E; Fong K; Nanno M; Ioannides CG; Trotta PP
    Anticancer Res; 1989; 9(4):849-58. PubMed ID: 2817813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
    Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
    J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.
    Brunda MJ; Rosenbaum D
    Cancer Res; 1984 Feb; 44(2):597-601. PubMed ID: 6692364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
    Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M
    Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of interferon-alpha (MOR-22) on human NK cell activity].
    Yanagihara Y; Tochizawa S; Ishii K; Hirai Y
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):342-8. PubMed ID: 3947110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
    Maluish AE; Ortaldo JR; Conlon JC; Sherwin SA; Leavitt R; Strong DM; Weirnik P; Oldham RK; Herberman RB
    J Immunol; 1983 Jul; 131(1):503-7. PubMed ID: 6863923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of interferon-alpha 2 and interleukin-2 on natural killer cell activity in patients with acquired immune deficiency syndrome.
    Reddy MM; Chinoy P; Grieco MH
    J Biol Response Mod; 1984 Aug; 3(4):379-86. PubMed ID: 6332880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
    Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
    J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells.
    Okabe M; Gomi K; Morimoto M; Nakamizo N
    Jpn J Cancer Res; 1985 Jul; 76(7):608-17. PubMed ID: 3928557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity.
    Golub SH; D'Amore P; Rainey M
    J Natl Cancer Inst; 1982 May; 68(5):711-7. PubMed ID: 6175788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
    Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
    Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant interferon-alpha on immune function in cancer patients.
    Maluish AE; Leavitt R; Sherwin SA; Oldham RK; Herberman RB
    J Biol Response Mod; 1983; 2(5):470-81. PubMed ID: 6358423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The augmentation of human natural killer cell activity by interferon-gamma is not associated with the induction of the interferon-alpha-inducible proteins.
    Gustafsson A; Sundström S; Lundgren E
    J Immunol; 1986 Jul; 137(1):167-71. PubMed ID: 3086447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes.
    Verhagen A; Mackay IR; Rowley M; Tymms M
    Nat Immun Cell Growth Regul; 1990; 9(5):325-33. PubMed ID: 2077397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.